TotipotentRX and ThermoGenesis (KOOL) Announce Successful Launch of Bone Marrow Transplant Program
8/8/2013 9:39:56 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RANCHO CORDOVA, Calif. and LOS ANGELES and NEW DELHI, India, Aug. 8, 2013 (GLOBE NEWSWIRE) -- TotipotentRX Corporation ("TotiRX"), Fortis Memorial Research Institute ("Fortis") and ThermoGenesis Corp. (Nasdaq:KOOL) today announced the successful launch of their pediatric bone marrow transplant program at the Fortis-TotiRX Centre for Cellular Medicine in New Delhi, India. This week, the new program achieved its first 100-day survival milestone following an allogeneic bone marrow engraftment in a pediatric patient with aplastic anemia using a donor with ABO-incompatible bone marrow having a major blood group mismatch (Patient B+ve, Donor A+ve). The successful transplant was performed using the AXP® AutoXpress® Platform ("AXP"), and bone marrow software, a FDA and Drug Controller General of India ("DCGI") approved cell processing platform from ThermoGenesis Corp.
Help employers find you! Check out all the jobs and post your resume.
comments powered by